20 citations
,
March 2017 in “Arthritis research & therapy” In this study, researchers analyzed social media data to assess the comparative safety of arthritis medications, finding increased odds of herpes zoster and perforated bowel with certain therapies. Social media posts expressed more safety concerns than favorable opinions about drug safety.
June 2014 in “Dermatology Times E-News” An arthritis drug helped a person with severe hair loss regrow their hair.
This creative piece by Christa Fairbrother poetically explores the experiences of living with arthritis, with no new research findings reported.
223 citations
,
September 2018 in “Rheumatology” This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.
31 citations
,
February 2014 in “Inflammation Research” This study found that reduced expression of CD200R1 on monocyte-derived macrophages in rheumatoid arthritis patients was significantly associated with higher disease severity and an imbalance in Th17/Treg cells.
24 citations
,
June 2016 in “Acta dermato-venereologica” In this case report, tofacitinib was associated with new hair growth on psoriasis lesions after three months of treatment.
20 citations
,
June 2024 in “Journal of Autoimmunity” This study found that in rheumatoid arthritis patients, inflammatory macrophages activate steroid metabolism to increase glucocorticoid and androgen production, which helps suppress inflammation and attenuate hyperproliferation in synovial fibroblasts, with notable disturbances seen in postmenopausal women due to diminished inactive steroid precursors.
20 citations
,
June 2019 in “JAAD Case Reports” This article reviews the use of tofacitinib for rheumatoid and psoriatic arthritis and alopecia areata, noting potential serious side effects, but reports no cases of palmoplantar pustulosis from the therapy.
8 citations
,
August 2016 in “Journal of the European Academy of Dermatology and Venereology” Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
7 citations
,
November 1977 in “JAMA” This case report describes group A streptococcal septicemia with monoarticular arthritis linked to an infected IUD, likely transmitted through sexual foreplay in a 28-year-old woman.
6 citations
,
May 2018 in “Zeitschrift für Rheumatologie” This case report describes a 56-year-old woman with rheumatoid arthritis who developed alopecia universalis during treatment with the TNF inhibitor adalimumab, with no hair regrowth after stopping the medication.
6 citations
,
December 2015 in “Medwave” This article presents a case of alopecia universalis linked to leflunomide use and reviews its application in rheumatoid arthritis treatment, highlighting potential adverse effects.
5 citations
,
October 2024 in “Reumatismo” This study reports a notable case of a patient with psoriatic arthritis and alopecia universalis who experienced significant improvement in both conditions after treatment with the JAK1 selective inhibitor upadacitinib, suggesting its potential efficacy for alopecia universalis, especially in cases involving inflammatory arthritis.
3 citations
,
August 2020 in “Case Reports in Dermatology” This case report suggests that JAK inhibitors like tofacitinib may effectively treat alopecia in patients with complex cases involving both rheumatological and dermatological conditions.
2 citations
,
October 2023 in “Frontiers in Immunology” In this study, researchers used Mendelian randomization to find a significant genetic association between rheumatoid arthritis and an increased risk of alopecia areata, suggesting RA patients should be vigilant for potential AA development.
1 citations
,
November 2025 in “Frontiers in Immunology” This review explores the complex role of the Innate Immune System in rheumatoid arthritis, highlighting gaps in understanding its functions and interactions with the Adaptive Immune System, offering insights into potential biomarkers and therapeutic strategies for this challenging autoimmune condition.
1 citations
,
November 2020 in “International Journal of Dermatology” In this case report, the authors suggest that methotrexate-induced rheumatoid papular eruption is a rare side effect of methotrexate, resolved after discontinuation, which may be linked to rheumatic conditions.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
1 citations
,
March 1989 in “The BMJ” A woman's hair grew back while she was taking sulphasalazine for arthritis.
February 2026 in “Annals of Case Reports” In this study, a patient with over 40 years of Alopecia Universalis achieved complete regrowth of hair on the scalp and eyebrows within less than three years after consistent treatment with oral Tofacitinib, suggesting its potential as a promising therapy for this condition.
July 2025 in “Journal of Investigative Dermatology” IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.
April 2025 in “International Journal of Dermatology” This abstract does not report any research results but mentions researcher affiliations and potential conflicts of interest, indicating the researchers' involvement in various pharmaceutical collaborations.
November 2024 in “Journal of Investigative Dermatology” Polygenic Score can help predict severe psoriasis and psoriatic arthritis.
October 2024 in “BMJ Case Reports” This case report describes a patient with both rheumatoid arthritis and alopecia areata who showed improvement in both conditions after treatment with baricitinib monotherapy, highlighting the importance of personalized treatment approaches in managing co-occurring autoimmune diseases.
April 2024 in “JEADV clinical practice” This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.
January 2024 in “Pharmacoepidemiology” This study found that patients with rheumatoid arthritis taking tofacitinib had higher rates of serious adverse events compared to those with alopecia areata, highlighting the need for careful assessment when using it off-label for alopecia areata.
September 2023 in “Journal of the American Academy of Dermatology” This study found that the incidence of major adverse cardiovascular events in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis who received Ixekizumab was low and stable over 3 to 5 years across 25 clinical trials.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” This case report identified a distinct pattern of scarring alopecia with folliculocentric noncaseating granulomas, linked with granulomatous dermatitis in the breast, as a potential cutaneous manifestation of rheumatoid arthritis.
May 2023 in “Zenodo (CERN European Organization for Nuclear Research)” This study reports a case of pyoderma gangrenosum in a patient with rheumatoid arthritis, emphasizing the need to consider it as a differential diagnosis when ulcerative skin lesions resemble vasculitis.
June 2022 in “C&EN global enterprise” This source notes that Olumiant (baricitinib), a rheumatoid arthritis drug by Eli Lilly and Company, has been approved as the first systemic treatment for severe alopecia areata.